Ana Rita Freitas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Rita Freitas has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ana Duarte Mendes
Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
2 shared publications - Marta Vaz Batista
Oncology Department, Hospital Professor Doutor Fernando Fonseca EPE, Amadora, Portugal
2 shared publications - Rodrigo Vicente
Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, 2720-276 Amadora, Portugal
2 shared publications - Sofia Braga
Medical Oncology Department, Hospital Prof. Doutor Fernando Fonseca, 2720-276 Amadora, Portugal
2 shared publications - Ana Fortuna
Unidade Local de Saúde do Algarve, Portugal
1 shared publication - Ana Sofia Spencer
Department of Oncology, Unidade Local de Saúde Santa Maria Lisboa, Avenida Professor Egas Moniz, 1649-035 Lisboa, Portugal
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (10)
Decoding low-density neutrophils in breast and lung cancer: from bystanders to drivers
Neutrophils, once viewed as short-lived and functionally uniform antimicrobial cells, are now recognized as highly plastic immune regulators with context-dependent roles in cancer. Among circulating neutrophil subsets, low-density neutrophils have emerged as a clinically relevant population in oncology due to their distinct phenotypic, potent immunosuppressive activity, and strong association with disease progression. Low-density neutrophils are rare in healthy individuals but markedly expanded in patients with solid tumors. Low-density neutrophils display enhanced activation, increased expression of immunoregulatory molecules such as programmed death-ligand 1, elevated reactive oxygen species production, and a heightened propensity for neutrophil extracellular trap formation, collectively impairing cytotoxic T cell function and promoting tumor immune evasion. Although low-density neutrophils have been described across multiple malignancies, their biological and clinical relevance has been most characterized in breast and lung cancers. This review synthesizes current knowledge on neutrophil biology, emphasizing the clinical and mechanistic features of low-density neutrophils, with a focus on these 2 tumor types. In breast cancer, increased low-density neutrophil abundance correlates with metastatic disease, poor response to neoadjuvant chemotherapy, immunosuppression, accelerated progression, and reduced survival. In lung cancer, elevated low-density neutrophil frequencies similarly associate with advanced disease stage, unfavorable clinical outcomes, and distinct surface marker profiles distinguishing them from high-density neutrophils. Mechanistic studies indicate that tumor-derived cytokines and chronic inflammation drive low-density neutrophil expansion, functional reprogramming, and tissue trafficking, linking systemic neutrophil dysregulation to advanced disease and metastatic progression. Finally, we highlight emerging biomarkers, unresolved challenges, and therapeutic strategies targeting neutrophil plasticity and low-density neutrophil-mediated immunosuppression, underscoring their potential as actionable components in precision oncology.
- 28 September 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (10)
Open AccessDecoding low-density neutrophils in breast and lung cancer: from bystanders to drivers
Neutrophils, once viewed as short-lived and functionally uniform antimicrobial cells, are now recognized as highly plastic immune regulators with context-dependent roles in cancer. Among circulating neutrophil subsets, low-density neutrophils have emerged as a clinically relevant population in oncology due to their distinct phenotypic, potent immunosuppressive activity, and strong association with disease progression. Low-density neutrophils are rare in healthy individuals but markedly expanded in patients with solid tumors. Low-density neutrophils display enhanced activation, increased expression of immunoregulatory molecules such as programmed death-ligand 1, elevated reactive oxygen species production, and a heightened propensity for neutrophil extracellular trap formation, collectively impairing cytotoxic T cell function and promoting tumor immune evasion. Although low-density neutrophils have been described across multiple malignancies, their biological and clinical relevance has been most characterized in breast and lung cancers. This review synthesizes current knowledge on neutrophil biology, emphasizing the clinical and mechanistic features of low-density neutrophils, with a focus on these 2 tumor types. In breast cancer, increased low-density neutrophil abundance correlates with metastatic disease, poor response to neoadjuvant chemotherapy, immunosuppression, accelerated progression, and reduced survival. In lung cancer, elevated low-density neutrophil frequencies similarly associate with advanced disease stage, unfavorable clinical outcomes, and distinct surface marker profiles distinguishing them from high-density neutrophils. Mechanistic studies indicate that tumor-derived cytokines and chronic inflammation drive low-density neutrophil expansion, functional reprogramming, and tissue trafficking, linking systemic neutrophil dysregulation to advanced disease and metastatic progression. Finally, we highlight emerging biomarkers, unresolved challenges, and therapeutic strategies targeting neutrophil plasticity and low-density neutrophil-mediated immunosuppression, underscoring their potential as actionable components in precision oncology.
- Open Access
Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing
Background: Platinum-based chemotherapy (PBC) followed by avelumab maintenance is a treatment option for patients with advanced urothelial carcinoma (aUC) patients. However, the optimal treatment sequencing in the era of antibody–drug conjugates (ADCs) is yet to be determined. Recent studies suggest that the timing of immune checkpoint inhibitor (ICI) administration may impact patient outcomes, with a potential benefit from morning infusions. Methods: This retrospective study included 105 patients with aUC treated with avelumab in Portugal and intended to assess the safety and clinical outcomes (progression-free survival (PFS), overall survival (OS), and overall response rate (ORR)) and evaluate the impact of treatment timing (morning vs. afternoon) on patient outcomes. Results: The median follow-up from the start of avelumab was 17.7 months, the median PFS (mPFS) was 9.8 months (95% CI 4.9–14.7), and the median OS (mOS) was 39.5 months (95% CI 13.2–65.7). Immune-related adverse events (irAEs) were reported in 65.8% of patients, with 6.7% experiencing G3 irAEs. Among those who received a subsequent-line ADC upon disease progression (43%), the mOS from the start of avelumab was 23.1 months (95% CI 9.2–37.0). Multivariate analysis showed significant improvement in mOS with morning avelumab infusions (HR 0.35, 95% CI: 0.12–0.97, p = 0.042) and a trend towards improved mPFS (HR 0.43, 95% CI: 0.179–1.02, p = 0.055). Conclusions: This study confirms the clinical efficacy and safety of avelumab, showing improved outcomes over JAVELIN Bladder 100 and suggesting that morning infusions may offer a survival benefit in this context. Further research is needed to optimize treatment sequencing and explore the impact of infusion timing in ICI strategies.
Open AccessAvelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing
Background: Platinum-based chemotherapy (PBC) followed by avelumab maintenance is a treatment option for patients with advanced urothelial carcinoma (aUC) patients. However, the optimal treatment sequencing in the era of antibody–drug conjugates (ADCs) is yet to be determined. Recent studies suggest that the timing of immune checkpoint inhibitor (ICI) administration may impact patient outcomes, with a potential benefit from morning infusions. Methods: This retrospective study included 105 patients with aUC treated with avelumab in Portugal and intended to assess the safety and clinical outcomes (progression-free survival (PFS), overall survival (OS), and overall response rate (ORR)) and evaluate the impact of treatment timing (morning vs. afternoon) on patient outcomes. Results: The median follow-up from the start of avelumab was 17.7 months, the median PFS (mPFS) was 9.8 months (95% CI 4.9–14.7), and the median OS (mOS) was 39.5 months (95% CI 13.2–65.7). Immune-related adverse events (irAEs) were reported in 65.8% of patients, with 6.7% experiencing G3 irAEs. Among those who received a subsequent-line ADC upon disease progression (43%), the mOS from the start of avelumab was 23.1 months (95% CI 9.2–37.0). Multivariate analysis showed significant improvement in mOS with morning avelumab infusions (HR 0.35, 95% CI: 0.12–0.97, p = 0.042) and a trend towards improved mPFS (HR 0.43, 95% CI: 0.179–1.02, p = 0.055). Conclusions: This study confirms the clinical efficacy and safety of avelumab, showing improved outcomes over JAVELIN Bladder 100 and suggesting that morning infusions may offer a survival benefit in this context. Further research is needed to optimize treatment sequencing and explore the impact of infusion timing in ICI strategies.
- Open Access
- 22 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16589
Adipocyte Microenvironment in Ovarian Cancer: A Critical Contributor?
Ovarian cancer is one of the most common gynecological malignancies and has low survival rates. One of the main determinants of this unfavorable prognosis is the high rate of peritoneal metastasis at diagnosis, closely related to its morbidity and mortality. The mechanism underlying peritoneal carcinomatosis is not clearly defined, but a clear preference for omental spread has been described. Growing evidence suggests that adipose tissue plays a role in promoting cancer onset and progression. Moreover, obesity can lead to changes in the original functions of adipocytes, resulting in metabolic and inflammatory changes in the adipose tissue microenvironment, potentially increasing the risk of tumor growth. However, the specific roles of adipocytes in ovarian cancer have not yet been fully elucidated. Due to the undeniable link between obesity and cancer, the adipose tissue microenvironment could also present a promising therapeutic target that warrants further research. This review discusses the complex relationship between ovarian cancer and the adipose tissue microenvironment.
- 22 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16589
Open AccessAdipocyte Microenvironment in Ovarian Cancer: A Critical Contributor?
Ovarian cancer is one of the most common gynecological malignancies and has low survival rates. One of the main determinants of this unfavorable prognosis is the high rate of peritoneal metastasis at diagnosis, closely related to its morbidity and mortality. The mechanism underlying peritoneal carcinomatosis is not clearly defined, but a clear preference for omental spread has been described. Growing evidence suggests that adipose tissue plays a role in promoting cancer onset and progression. Moreover, obesity can lead to changes in the original functions of adipocytes, resulting in metabolic and inflammatory changes in the adipose tissue microenvironment, potentially increasing the risk of tumor growth. However, the specific roles of adipocytes in ovarian cancer have not yet been fully elucidated. Due to the undeniable link between obesity and cancer, the adipose tissue microenvironment could also present a promising therapeutic target that warrants further research. This review discusses the complex relationship between ovarian cancer and the adipose tissue microenvironment.
- Open Access
- 9 January 2023
- Published by Springer Nature in Cureus
- Vol. 14 (11) , c91
Correction
This article has been corrected at the request of the authors due to an error in the author order when originally published. The authors deeply regret that this error was not identified and corrected prior to publication. The correct author order is now shown.
- 9 January 2023
- Published by Springer Nature in Cureus
- Vol. 14 (11) , c91
Open AccessCorrection
This article has been corrected at the request of the authors due to an error in the author order when originally published. The authors deeply regret that this error was not identified and corrected prior to publication. The correct author order is now shown.